Sebastian Hoberuck

Dresden, SN, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Ablative radiotherapy in castration-resistant prostate cancer.

Ablative radiotherapy in castration-resistant prostate cancer.

Journal: BJU international

Published: July 02, 2026

[ 68 Ga]Ga-NECT-224 PET/CT Shows Increasing Nectin-4 Expression in Progressive Urothelial Carcinoma Under ADC-Therapy With Enfortumab-Vedotin.

[ 68 Ga]Ga-NECT-224 PET/CT Shows Increasing Nectin-4 Expression in Progressive Urothelial Carcinoma Under ADC-Therapy With Enfortumab-Vedotin.

Journal: Clinical nuclear medicine

Published: February 10, 2026

Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry.

Salvage Radiotherapy Confers an Overall Survival Advantage in Biochemical Recurrence of Prostate Cancer: Evidence from the International PROMISE Registry.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: December 04, 2025

A convolutional neural network for fully automated total metabolic tumor volume delineation in patients with aggressive Non-Hodgkin lymphoma.

A convolutional neural network for fully automated total metabolic tumor volume delineation in patients with aggressive Non-Hodgkin lymphoma.

Journal: European journal of nuclear medicine and molecular imaging

Published: November 11, 2025

"Precision on Two Wheels"─Structural Refinement of 64Cu- and 68Ga-Labeled Bicyclic Peptides Targeting Nectin-4 for Improved Tumor Imaging: From Preclinical Development to First-in-Human Application.

"Precision on Two Wheels"─Structural Refinement of 64Cu- and 68Ga-Labeled Bicyclic Peptides Targeting Nectin-4 for Improved Tumor Imaging: From Preclinical Development to First-in-Human Application.

Journal: Journal of medicinal chemistry

Published: October 13, 2025

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study.

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study.

Journal: The Lancet. Oncology

Published: September 24, 2025

Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET/CT.

Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET/CT.

Journal: BJU international

Published: August 23, 2025

Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry.

Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry.

Journal: European urology

Published: July 01, 2025

[68Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy.

[68Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 22, 2025

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study.

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study.

Journal: European urology

Published: January 23, 2025

Herpes Zoster-induced Ganglioneuritis With Corresponding Shingles Dermatome and Its Regression Within 10 Weeks Following 6 Cycles of BEACOPP Chemotherapy.

Herpes Zoster-induced Ganglioneuritis With Corresponding Shingles Dermatome and Its Regression Within 10 Weeks Following 6 Cycles of BEACOPP Chemotherapy.

Journal: Clinical nuclear medicine

Published: November 04, 2024

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study.

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study.

Journal: The Lancet. Oncology

Published: April 23, 2024

Showing 1-12 of 38

Last Updated: 09/26/2026